Seer (SEER) Competitors

Standard BioTools (NASDAQ:LAB) and Seer (NASDAQ:SEER) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Which has preferable valuation & earnings, LAB or SEER?

Seer has lower revenue, but higher earnings than Standard BioTools. Standard BioTools is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Standard BioTools	$174.43M	2.67	-$138.88M	-$0.35	-3.50
Seer	$14.17M	8.83	-$86.60M	-$1.41	-1.51

Do analysts prefer LAB or SEER?

Standard BioTools presently has a consensus price target of $2.50, suggesting a potential upside of 104.08%. Seer has a consensus price target of $3.00, suggesting a potential upside of 41.18%. Given Standard BioTools' stronger consensus rating and higher possible upside, equities research analysts clearly believe Standard BioTools is more favorable than Seer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Standard BioTools	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Seer	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Is LAB or SEER more profitable?

Standard BioTools has a net margin of -78.24% compared to Seer's net margin of -560.90%. Standard BioTools' return on equity of -22.44% beat Seer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Standard BioTools	-78.24%	-22.44%	-16.74%
Seer	-560.90%	-24.69%	-22.13%

Does the media favor LAB or SEER?

In the previous week, Seer had 5 more articles in the media than Standard BioTools. MarketBeat recorded 6 mentions for Seer and 1 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 1.89 beat Seer's score of 0.10 indicating that Standard BioTools is being referred to more favorably in the media.

Company	Overall Sentiment
Standard BioTools	Very Positive
Seer	Neutral

Do institutionals and insiders hold more shares of LAB or SEER?

53.7% of Standard BioTools shares are held by institutional investors. Comparatively, 75.2% of Seer shares are held by institutional investors. 23.2% of Standard BioTools shares are held by insiders. Comparatively, 11.3% of Seer shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Which has more volatility & risk, LAB or SEER?

Standard BioTools has a beta of 1.54, suggesting that its stock price is 54% more volatile than the S&P 500. Comparatively, Seer has a beta of 1.57, suggesting that its stock price is 57% more volatile than the S&P 500.

Summary

Standard BioTools beats Seer on 10 of the 16 factors compared between the two stocks.